FN2 Earnings Intelligence
Regeneron Pharmaceuticals, Inc. income statement (quarterly)
Regeneron Pharmaceuticals, Inc. (REGN) Income Statement (quarterly) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 est. | 12/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $3,090.2 | $1,995.8 | $2,506.4 | $2,962.6 | $2,455.8 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $3,028.7 | $3,675.6 | $3,754.3 | $3,605.4 | $4,290.7 | $4,561.9 | $5,280.9 |
| % Growth | - | - | - | - | - | 21.5% | - |
| Gross Profit | $2,763.2 | $3,400 | $3,473.3 | $3,232 | $3,930 | - | - |
| % Margin | 91.2% | 92.5% | 92.5% | 89.6% | 91.6% | - | - |
| EBITDA | $718.6 | - | - | $766.1 | - | - | - |
| % Margin | 23.7% | - | - | 21.2% | - | - | - |
| Net Income | $808.7 | $1,391.6 | $1,460 | $727.2 | $1,296.9 | - | - |
| % Margin | 26.7% | 37.9% | 38.9% | 20.2% | 30.2% | - | - |
| Diluted EPS | $7.27 | $12.81 | $13.62 | $6.75 | $12.23 | $16.36 | $20.81 |
| % Growth | - | - | - | - | - | 20.1% | - |
| Operating Cash Flow | $1,045.1 | - | - | $1,078.9 | - | - | - |
| CapEx | $229.3 | - | - | $230.6 | - | - | - |
| Free Cash Flow | $815.8 | - | - | $848.3 | - | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 est. | 12/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $3,028.7 | $3,675.6 | $3,754.3 | $3,605.4 | $4,290.7 | $4,561.9 | $5,280.9 |
| Gross Profit | $2,763.2 | $3,400 | $3,473.3 | $3,232 | $3,930 | - | - |
| EBITDA | $718.6 | - | - | $766.1 | - | - | - |
| Net Income | $808.7 | $1,391.6 | $1,460 | $727.2 | $1,296.9 | - | - |
| Diluted EPS | $7.27 | $12.81 | $13.62 | $6.75 | $12.23 | $16.36 | $20.81 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $3,090.2 | $1,995.8 | $2,506.4 | $2,962.6 | $2,455.8 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $1,984.8 | $1,985.1 | $1,985.5 | $1,986.2 | $1,986.6 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | $1,045.1 | - | - | $1,078.9 | - |
| Capital Expenditure | $229.3 | - | - | $230.6 | - |
| Free Cash Flow | $815.8 | - | - | $848.3 | - |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Gross Margin | 91.2% | 92.5% | 92.5% | 89.6% | 91.6% |
| EBITDA Margin | 23.7% | - | - | 21.2% | - |
| Net Margin | 26.7% | 37.9% | 38.9% | 20.2% | 30.2% |
| FCF Margin | 26.9% | - | - | 23.5% | - |
| Diluted EPS Growth | - | - | - | - | - |
Get the REGN recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.